Anti-Amyloid Monoclonal Antibody Therapy

Immunotherapies for Treating Alzheimer’s Disease

The Cognitive Neurology Unit at Beth Israel Deaconess Medical Center (BIDMC) is treating patients with Alzheimer's disease using monoclonal, anti-amyloid therapy, including lecanemab.

These medications are available to patients whose Alzheimer’s diagnosis was confirmed via cerebrospinal fluid (CSF) markers or amyloid-PET imaging. Both medications require intravenous infusions (performed at the BIDMC infusion clinic) every two weeks for up to 18 months. Though the risk is small, potential side effects include brain swelling and brain bleeding.

Request an Evaluation

If you're interested in anti-amyloid therapy (lecanemab) for the treatment of Alzheimer's disease, you can request an evaluation with our DIAD clinic by completing and submitting the BIDMC enrollment form.